Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/228561
Share/Export:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens

AuthorsBlasco, Lucía; Ambroa, Antón; Trastoy, Rocío; Bleriot, Inés; Moscoso, Miriam CSIC ORCID; Fernández-García, Laura; Pérez-Nadales, Elena; Fernández-Cuenca, Felipe; Torre-Cisneros, Julián; Oteo, Jesús; Oliver, Antonio; Cantón, Rafael; Kiid, Tim; Navarro, Ferrán; Miró, Elisenda; Pascual, Álvaro; Bou, Germán; Martínez-Martínez, Luis; Tomás, María
Issue Date28-Apr-2020
PublisherSpringer Nature
CitationScientific Reports 10: 7163 (2020)
AbstractThe emergence of multidrug resistant (MDR) pathogenic bacteria is jeopardizing the value of antimicrobials, which had previously changed the course of medical science. In this study, we identified endolysins ElyA1 and ElyA2 (GH108-PG3 family), present in the genome of bacteriophages Ab1051Φ and Ab1052Φ, respectively. The muralytic activity of these endolysins against MDR clinical isolates (Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae) was tested using the turbidity reduction assay. Minimal inhibitory concentrations (MICs) of endolysin, colistin and a combination of endolysin and colistin were determined, and the antimicrobial activity of each treatment was confirmed by time kill curves. Endolysin ElyA1 displayed activity against all 25 strains of A. baumannii and P. aeruginosa tested and against 13 out of 17 strains of K. pneumoniae. Endolysin ElyA2 did not display any such activity. The combined antimicrobial activity of colistin and ElyA1 yielded a reduction in the colistin MIC for all strains studied, except K. pneumoniae. These results were confirmed in vivo in G. mellonella survival assays and in murine skin and lung infection models. In conclusion, combining colistin (1/4 MIC) with the new endolysin ElyA1 (350 µg) enhanced the bactericidal activity of colistin in both in vitro and in vivo studies. This will potentially enable reduction of the dose of colistin used in clinical practice.
Publisher version (URL)http://doi.org/10.1038/s41598-020-64145-7
URIhttp://hdl.handle.net/10261/228561
Identifiersdoi: 10.1038/s41598-020-64145-7
e-issn: 2045-2322
Appears in Collections:(IBIS) Artículos

Files in This Item:
File Description SizeFormat
multi-drug_resistant.pdf3,84 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

Page view(s)

68
checked on Jan 22, 2022

Download(s)

45
checked on Jan 22, 2022

Google ScholarTM

Check


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.